Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
METHYLPREDNISOLONE ACETATE (UNII: 43502P7F0P) (METHYLPREDNISOLONE - UNII:X4W7ZR7023)
Teva Parenteral Medicines, Inc.
METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE ACETATE 40 mg in 1 mL
INTRA-ARTICULAR
PRESCRIPTION DRUG
When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. To tide the p
Methylprednisolone acetate injectable suspension, USP is available as single-dose vials in the following strengths and package sizes: 40 mg per mL NDC 0703-0031 -01 1 mL vials NDC 0703-0031 -04 25 x 1 mL vials 80 mg per mL NDC 0703-0051 -01 1 mL vials NDC 0703-0051 -04 25 x 1 mL vials Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured By: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054 Rev. F 6/2021
Abbreviated New Drug Application
METHYLPREDNISOLONE ACETATE- METHYLPREDNISOLONE ACETATE INJECTION, SUSPENSION TEVA PARENTERAL MEDICINES, INC. ---------- METHYLPREDNISOLONE ACETATE INJECTABLE SUSPENSION, USP SINGLE-DOSE VIAL NOT FOR INTRAVENOUS USE DESCRIPTION Methylprednisolone acetate injectable suspension, USP is an anti-inflammatory glucocorticoid for intramuscular, intra-articular, soft tissue or intralesional injection. It is available as single-dose vials in two strengths: 40 mg/mL, 80 mg/mL. Each mL of these preparations contains: Methylprednisolone acetate, USP ....................................40 MG .............80 MG Polyethylene glycol 3350 ................................................29 mg .............28 mg Myristyl-gamma-picolinium chloride...............................0.195 mg .........0.189 mg Sodium Chloride was added to adjust tonicity. When necessary, pH was adjusted with sodium hydroxide and/or hydrochloric acid. The pH of the finished product remains within the USP specified range (e.g., 3.0 to 7.0). The chemical name for methylprednisolone acetate, USP is pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-,(6α,11β)-. The structural formula is represented below: C H O M.W. 416.51 Methylprednisolone acetate injectable suspension, USP contains methylprednisolone 24 32 6 acetate, USP which is the 6-methyl derivative of prednisolone. Methylprednisolone acetate, USP is a white or practically white, odorless, crystalline powder which melts at about 215° with some decomposition. It is soluble in dioxane, sparingly soluble in acetone, alcohol, chloroform, and methanol, and slightly soluble in ether. It is practically insoluble in water. CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic analogs are used primarily for their anti-inflammatory effects in disorders o Citiți documentul complet